LISTING OF CLAIMS

1-10. (Canceled)

11. (Currently amended) A method of augmenting tissue in a subject that is in need of tissue augmentation, the method comprising:

a) inserting a needle into a subject at a location in the subject that is in need of tissue augmentation, wherein the needle is coupled to a syringe loaded with a crosslinked HA composition that includes crosslinked, water-insoluble, hydrated HA gel particles, wherein the HA includes crosslinks represented by the following structural formula:

HA'—U—R_2—U—HA'

wherein:

each HA' is the same or different crosslinked HA' molecule;

each U is independently an optionally substituted O-acyl isourea or N-acyl urea;

and R_2 is optionally substituted alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, cycloalkynyl aryl, heteroaryl, heterocyclyl, cycloaliphaticalkyl, aralkyl, heteroaralkyl, or heterocyclylalkyl,

wherein the HA gel particles have an average particle diameter distribution selected from the group consisting of a hydrated particle average diameter between about 20 μm and about 1000 μm, and a dehydrated particle average diameter between about 10 μm and about 500 μm;

wherein the crosslinked HA composition is a single hydrated particle phase; and

b) applying force to the syringe, whereby at least a portion of the crosslinked HA composition is delivered into the subject;

wherein the crosslinked HA composition is stable in the subject for at least 8 weeks.

12. (original) The method of claim 11, wherein the subject is human.

13. (original) The method of claim 12, wherein the particles include at least one bioactive agent selected from the group consisting of cells, genes, proteins, antibodies, peptides, and pharmaceuticals.

14. (previously presented) The method of claim 13, wherein the bioactive agent includes an anesthetic.

15. (previously presented) The method of claim 14, wherein the anesthetic is lidocaine, mepivacaine, prilocaine, bupivacaine, cocaine, procaine, chlorocaine, or tetracaine, or a salt or solvate thereof.

16. (previously presented) The method of claim 15, wherein the anesthetic is lidocaine.HCl.

17. (canceled)

18. (previously presented) The method of claim 12, wherein the distribution is a multimodal distribution.

19. (original) The method of claim 18, wherein the HA in the composition consists essentially of the crosslinked, water-insoluble, hydrated HA gel particles.

20. (previously presented) The method of claim 12 wherein the crosslinked HA composition has at least one parameter measured at 37°C selected from a storage modulus G' of at least about 50 Pa when measured at 1 Hz frequency using a 4 cm flat geometry, and a kinematic viscosity of at least about 20,000 cPs when measured at a shear rate of 1 s^{-1}.

21. (original) The method of claim 20, wherein the composition has a storage modulus G' of at least about 100 Pa.

22. (original) The method of claim 21, wherein the composition has a storage modulus G' of at least about 400 Pa.

23-48. (canceled)